FDA approves esketamine treatment for MDD, suicidal ideation
Mental Health Weekly August 10, 2020 DOI: 10.1002/mhw.32471 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | News report Peer reviewed |
|---|---|
| Intervention | Esketamine |
| Topics | Depression Esketamine |
| Key points | The FDA approved an expanded indication for SPRAVATO (esketamine) nasal spray to treat major depressive disorder with acute suicidal ideation or behavior, in addition to its existing approval for treatment-resistant depression. |
Abstract
The Food and Drug Administration (FDA) announced Aug. 3 approval of Janssen Pharmaceutical's supplemental new drug application (sNDA) for the expanded use of SPRAVATO esketamine Clll nasal spray for the treatment of major depressive disorder (MDD) with acute suicidal ideation or behavior. SPRAVATO was initially approved by the FDA March 5, 2019, for the treatment of treatment‐resistant depression.
Citations in the library
Cited by 9
- Should Adolescents be Included in Emerging Psychedelic Research? Canadian Journal of Bioethics 2022
- The effect of low-dose esketamine on maternal depression after cesarean delivery. Journal of psychosomatic obstetrics and gynaecology December 1, 2025
- Psychedelics and Hallucinogens in Psychiatry: Finding New PharmacologicalTargets Current Topics in Medicinal Chemistry December 2, 2021
- Efficacy and safety of esketamine for "treatment resistant depression": registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. BMC Medicine November 28, 2025
- Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis. European Archives of Psychiatry and Clinical Neuroscience October 9, 2024
and 4 more in the library